证券代码：300294 证券简称：博雅生物 公告编号：2025-059 华润博雅生物制药集团股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券法》）、《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》（以下简称《上市公司规范运作指引》）、 《深圳证券交易所创业板股票上市规则》（以下简称《创业板上市规则》）、《上 市公司募集资金监管规则》《深圳证券交易所创业板上市公司自律监管指南第2 号——公告格式》相关格式指引的规定及要求，华润博雅生物制药集团股份有限 公司（以下简称公司或华润博雅生物）编制了截至2025年6月30日的"2025年半 年度募集资金存放与使用情况的专项报告"。具体情况如下： 一、2018 年非公开发行募集资金基本情况 （一）募集资金金额和实际到账时间 根据公司2017年第二次临时股东大会会议决议及中国证券监督管理委员会 《关于核准博雅生物制药集团股份有限公司非公开发行股票的批 ...

| 非经营性资金占用 | 资金占用方 | | 占用方与上市 | 上市公司 | 2025 年期初 | | 2025 年半年度占 用累计发生金额 | 2025 | 年半年度占 用资金的利息 | 2025 | 年半年度偿 | | 2025 | 年半年度期 | 占用形成原因 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | | 公司的关联关系 | 核算的会计科目 | 占用资金余额 | | | | | | 还累计发生金额 | | | 末占用资金余额 | | 占用性质 | | | | | | | | | (不含利息) | | (如有) | | | | | | | | | 控股股东、实际控制人 及其附属企业 | | 无 | 不适用 | 不适用 | | - | | - | | - | | - | | - | 不适用 | 不适用 | | 小计 | | | | | | - | | - | | - | | - | | - | | | | 前控股股东、 ...

证券代码：300294 证券简称：博雅生物 公告编号：2025-063 华润博雅生物制药集团股份有限公司 关于聘任董事会秘书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2025 年 8 月 21 日召开了第八届董事会第十五次会议，审议通过了《关于聘任董事会秘书的议案》， 具体情况如下： 一、董事会秘书辞任 公司于 2025 年 8 月 21 日收到梁化成提交的书面《辞任报告》，因工作调动， 梁化成申请辞去公司董事会秘书职务。根据《中华人民共和国公司法》《公司章 程》等相关规定，该辞任报告自送达公司董事会之日起正式生效。辞任后，梁化 成将继续担任公司第八届董事会董事、副总裁，不会影响公司相关工作的正常开 展。 截至本公告披露日，梁化成未直接持有公司股份，其不存在应当履行而未履 行的承诺事项。梁化成就任时确定的任期为 2024 年 03 月 21 日至 2027 年 03 月 20 日，辞任后，其在就任时确定的任期内和任期届满后六个月内，继续遵守《上 市公司董事和高级管理人员所持本公司股份及其变动管理规则》 ...

证券代码：300294 证券简称：博雅生物 公告编号：2025-060 华润博雅生物制药集团股份有限公司 关于使用银行承兑汇票支付募集资金投资项目资金 并以募集资金等额置换的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司、博雅生物）于2019 年4月15日召开第六届董事会第二十三次会议、第六届监事会第二十次会议，会 议审议通过了《关于使用银行承兑汇票支付募投项目所需资金并以募集资金等额 置换的议案》，同意公司在募集资金投资项目（以下简称募投项目）实施期间， 根据实际情况使用银行承兑汇票支付募投项目中的应付工程款、设备采购款、材 料采购款等款项，并从募集资金账户划转等额资金至公司自有资金账户。具体内 容详见公司于2019年4月15日在巨潮资讯网上披露的《关于使用银行承兑汇票支 付募投项目所需资金并以募集资金等额置换的公告》。 | 加：本年度募集资金理财产品收益、利息收入减除手续费净额 | 13,315,616.97 | | --- | --- | | 二、使用配套募集资金 | 1,085,783,062.77 | ...

Core Viewpoint - The company plans to divest 80% of its stake in Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. to focus on its core blood products business and optimize resource allocation, enhancing capital return levels [1][3]. Group 1: Transaction Details - The transaction will be conducted through a public listing on the Shanghai United Assets and Equity Exchange, with an initial listing price of 213 million yuan, subject to the valuation approved by the state-owned assets supervision authority [1]. - After the completion of the share transfer, the company will hold 10.69% of Boya Xinhao, and it will no longer be included in the company's consolidated financial statements [2]. Group 2: Business Performance - In 2024, the company reported total revenue of 1.735 billion yuan, a decrease of 34.58% year-on-year, while net profit attributable to shareholders was 397 million yuan, an increase of 67.18% compared to the previous year [2]. - The company achieved a plasma collection of 630.6 tons in 2024, representing a year-on-year growth of 10.4%, with the main entity, China Resources Boya, collecting 522.04 tons, up 11.7%, exceeding the industry average growth rate [2]. Group 3: Strategic Implications - The divestiture is expected to optimize the company's business structure, focus on core development, enhance sustainable internal growth, facilitate capital flow, and activate existing production capacity, ultimately promoting high-quality development [3].

Market Overview - The Shanghai Composite Index closed at 3653.50 points, with a change of +0.51% [1] - The total trading volume of A-shares reached 1,149.623 billion yuan [1] Technical Analysis - A total of 17 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Angli (002940) with a distance of -1.91% - Chengdu Xian Dao (688222) with a distance of -1.51% - Saiseng Pharmaceutical (300485) with a distance of -1.38% [1] Individual Stock Performance - Angli (002940) saw a daily increase of 2.02% with a turnover rate of 4.48% [1] - Chengdu Xian Dao (688222) increased by 1.47% with a turnover rate of 2.10% [1] - Saiseng Pharmaceutical (300485) experienced a slight decrease of -0.14% with a turnover rate of 3.10% [1] - Other stocks with notable performance include: - Jintai (688443) up by 1.78% - Changshan Pharmaceutical (300255) up by 2.29% - Zhizheng (603991) down by -1.69% [1]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]

（文章来源：证券日报） 证券日报网讯博雅生物8月6日在互动平台回答投资者提问时表示，公司2025年7月31日含信用账户合并 名册的股东人数为29，062户。 ...

Market Overview - The Shanghai Composite Index closed at 3568.96 points, above the six-month moving average, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,180.388 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 99 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Mengsheng Electronics: 5.86% - Guanghong Technology: 4.32% - Jinyang Co., Ltd.: 3.70% [1] Detailed Stock Performance - Top performers on August 4th with deviation rates: - Mengsheng Electronics (688311): Today's change of 7.40%, turnover rate of 4.63%, six-month line at 37.68 yuan, latest price at 39.89 yuan [1] - Guanghong Technology (300735): Today's change of 6.10%, turnover rate of 4.73%, six-month line at 27.36 yuan, latest price at 28.54 yuan [1] - Jinyang Co., Ltd. (301210): Today's change of 5.60%, turnover rate of 15.69%, six-month line at 42.39 yuan, latest price at 43.96 yuan [1] Additional Notable Stocks - Other stocks with positive performance and deviation rates include: - Zhenjiang Co., Ltd. (603507): 5.00% change, 12.19% turnover, six-month line at 24.79 yuan, latest price at 25.60 yuan [1] - Baiao Chemical (603360): 5.59% change, 2.66% turnover, six-month line at 20.51 yuan, latest price at 21.16 yuan [1] - Stocks with smaller deviation rates that just crossed the six-month line include: - Deep Technology (300735): 6.10% change, 4.73% turnover, six-month line at 27.36 yuan, latest price at 28.54 yuan [1] - Qiming Information (301210): 5.60% change, 15.69% turnover, six-month line at 42.39 yuan, latest price at 43.96 yuan [1]

Group 1 - The A-share biopharmaceutical sector experienced a short-term surge, with Tian Tan Biological reaching the daily limit, and Wan Ze Shares previously hitting the limit as well [1] - Other companies such as Aidi Pharmaceutical, Zhifei Biological, Boya Biological, Bohui Innovation, and Pailin Biological also saw increases in their stock prices [1] - The news is driven by the completion of China's first copy-type Tian Tan smallpox vaccine carrier HIV vaccine Phase I clinical trial by teams from the Chinese Center for Disease Control and Prevention and the AIDS Prevention Center [1]